Key facts
- It has raised $17.1M; the latest was Later Stage VC ($5.3M) in Dec 2024.
- Notable investors include Alumni Ventures, Oost NL, Sanquin, Broadview Ventures, Okklo Life Sciences — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Alveron Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Alveron Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alveron Pharma
Developer of a coagulation technology designed to create a cyclodextrin-based universal anticoagulant reversal drug. The company develops a ready-to-use injectable solution intended for the rapid reversal of anticoagulant or platelet inhibitor effects in patients with haemorrhagic stroke or intracranial haemorrhage, enabling medical practitioners to treat bleeding emergencies more quickly and effectively.
- Sector
- Healthcare
- HQ
- Oss, Netherlands
- Founded
- 2019
- Employees
- 7
- Website
- alveron.com/
- Ownership
- Privately Held (backing)
Alveron Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alveron Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alveron Pharma in its N-PORT filings yet. We sweep new filings monthly.